Compare CVS Health Corp (CVS) vs TKO Group Holdings Inc (TKO) Price & Performance

CVS Health trades at $86.16, down 2.04% for the day, amid a bearish technical signal. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.58 exceeding the $1.85 estimate. Revenue grew to $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst consensus is overwhelmingly positive, with 35 of 41 analysts rating the stock a Buy and a consensus price target of $111.20, implying significant upside. Recent news highlights Aetna's 2027 Medicare plan updates and a quarterly dividend declaration.

The outlook for CVS remains favorable based on fundamental strength and analyst optimism, but risks include reimbursement pressure, regulatory scrutiny, and a high debt load. The stock's current valuation metrics, such as a P/E of 23.17 and P/S of 0.27, appear reasonable relative to historical levels, supporting a constructive view for long-term investors despite near-term technical weakness.

TKO trades at $179.38, up 0.41% on the day, but technical indicators signal a bearish trend with the stock near a 52-week low of $174.58 (Defense World, 2026-10-02). The company reported mixed Q2 2026 earnings, missing EPS estimates but raising full-year guidance. Revenue growth remains solid, with 2026 projections at $5.3B, though profitability margins are thin at 4.33% net income margin. A quarterly dividend of $0.79 was declared for payment in September 2026.

Wall Street maintains a bullish stance with 89% buy ratings and a $227 consensus price target, implying significant upside. Key risks include execution on media rights deals, competitive pressures in sports entertainment, and reliance on live events. The stock's high P/E of 63.73 suggests growth expectations must be met to justify valuation.